The Neurofibromatosis-associated Tumor Biobank

Neurofibromatoses Clinical Trial

Official title:

Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03359304
• Other study ID #: PKU-MPNST
• Status: Not yet recruiting
• Phase: N/A
• First received: November 25, 2017
• Last updated: November 29, 2017
• Start date: March 1, 2018
• Est. completion date: March 1, 2028

Study information

• Verified date: November 2017
• Source: Peking University People's Hospital
• Contact: Kuisheng Liu, phD
• Phone: +8601088324471
• Email: tumorcenter[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research

Description:

Samples of blood and other stored material such as slides,frozen tissues or leftover diagnostic material.

Questionnaire information, including health history, growth and development, physical activity and family medical history information.

If patients have been diagnosed with a neurofibromatosis-associated tumor or another condition the investigator is interested in， the investigator will ask the patient to release medical record information relating to diagnosis and treatment of neurofibromatosis-associated tumor, other cancers, blood disorders, and similar conditions.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: March 1, 2028
• Est. primary completion date: March 1, 2023
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Proband Inclusion criteria: A diagnosis or suspected diagnosis of neurofibromatosis-associated tumor Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with neurofibromatosis-associated tumor

Exclusion Criteria:

non-asian

Related Conditions & MeSH terms

• Neurofibroma
• Neurofibromatoses

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ren tingting

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor	To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor	3 years